<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118064</url>
  </required_header>
  <id_info>
    <org_study_id>CC6</org_study_id>
    <nct_id>NCT02118064</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma</brief_title>
  <acronym>CC6</acronym>
  <official_title>A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Advances Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Advances Inc.</source>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in
      patients with refractory colon cancer who had been previously treated with an
      Irinotecan-based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Evaluate the effect of G17DT-Irinotecan combination therapy on tumor response assessed by magnetic resonance imaging or computed tomography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival time</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The vital status of patients was monitored until death or end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-existing illnesses, were assessed at each visit.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>G17DT-Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G17DT-Irinotecan</intervention_name>
    <description>500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.</description>
    <arm_group_label>G17DT-Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically confirmed cancer of the colon or rectum or both and objective
             evidence of distant metastases

          -  Have measurable disease

          -  Have previously been treated with an irinotecan based chemotherapy

          -  Have progressive metastatic disease after an irinotecan containing chemotherapy
             regimen (alone or in combination) for metastatic colorectal cancer

          -  Be at least 18 years of age

          -  Have laboratory data as specified below:

               -  Aspartate aminotransferase (AST) and ALT less than 2.5 times upper limit of
                  normal

               -  Bilirubin less than 1.5 mg/dL (SI units, 25.65 mol/L)

               -  Creatinine less than 1.5 mg/dL (SI units, 132 mol/L)

               -  White blood cell (WBC) count greater than 3,000/mm3

               -  Platelets greater than 100,000/mm3

               -  Hemoglobin more than 9.5 g/dL (SI units, 5.9 mol/L)

               -  International normalized ratio of prothrombin time less than 1.2, and activated
                  partial thromboplastin time no more than 5 seconds above normal limits

          -  Have a life expectancy of at least 3 months

          -  Have a KPS score of 70 or greater

          -  Use contraceptive methods, if sexually active

          -  Have the ability to understand the requirements of the study, to provide written
             informed consent, agree to abide by the study restrictions, and agree to return for
             the required assessments

        Exclusion Criteria:

          -  Be pregnant or nursing

          -  Have only symptomatic locally recurrent colorectal cancer

          -  Have had any active cancer in addition to metastatic colorectal cancer within the last
             5 years except curatively treated nonmelanomatous skin cancer

          -  Have received any prior anticancer immunotherapy

          -  Have central nervous system metastasis, whether treated or not

          -  Have bone metastases as sole manifestation of metastatic colorectal cancer

          -  Have received chemotherapy within the previous 21 days

          -  Have had major surgery within 21 days

          -  Have immunodeficiency (primary or acquired)

          -  Have undergone bone marrow transplantation within the last year

          -  Require chronic administration of corticosteroids; inhaled corticosteroids for asthma
             and chronic obstructive pulmonary disease are allowed

          -  Use in the past 30 days or concomitant use of immunosuppressants, including systemic
             (i.e., oral or injected) corticosteroids

          -  Have participated in any clinical trial involving conventional or investigational
             drugs or devices within 21 days before G17DT irinotecan administration

          -  Have contraindication to irinotecan based therapy

          -  Have hypersensitivity to diphtheria toxoid

          -  Use in the past 14 days or chronic concomitant use of proton pump inhibitors

          -  Have uncontrolled serious cardiovascular or metabolic disease or any other
             uncontrolled serious medical or psychiatric illness

          -  Have any condition that is likely to detrimentally affect regular follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>G17DT</keyword>
  <keyword>irinotecan</keyword>
  <keyword>Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Gastrins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

